home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630561.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
34 lines
Document 0561
DOCN M9630561
TI Cost-effectiveness: from whose perspective?
DT 9603
AU Hillman AL; School of Medicine, University of Pennsylvania,
Philadelphia,; USA.
SO J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S14-8.
Unique Identifier : AIDSLINE MED/96075584
AB Evaluating the cost-effectiveness of medical interventions, particularly
pharmaceuticals, has been the focus of much debate in this country over
the past few years. Although the support for efficient utilization of
monies is widespread, the delicate balance between optimizing patient
outcome with the costs to do so in high-risk patients is especially
difficult. Although research in the field of cost-effectiveness is
widespread, at present there are few guidelines in this country.
Furthermore, the introduction of bias is a serious concern in the
interpretation and validation of studies, often limiting their utility.
Guidelines that can be implemented to minimize bias in economic research
have been identified to include administrative, methodology-based, and
ethical parameters. The standardization and implementation of such
guidelines can reduce bias in economic research and optimize study
validity. This review focuses on these issues and suggests that initial
steps to produce unbiased economic research include total disclosure,
appropriate comparator selection, complete release of all relevant data,
and the cooperation of all involved parties.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/ECONOMICS Antiviral
Agents/ECONOMICS Cost-Benefit Analysis/*TRENDS Economics,
Medical/STANDARDS Ethics, Professional Guidelines Human
Research/STANDARDS JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).